| Literature DB >> 31338117 |
Hosam Halim1, Alan Askari1, Rebecca Nunn1, James Hollingshead1.
Abstract
Introduction: Surgical management of Hinchey III and IV diverticulitis utilizes either Hartmann's procedure (HP) or primary resection anastomosis (PRA) with or without fecal diversion. The aim of this meta-analysis is to determine which of the two procedures has a more favorable outcome.Entities:
Keywords: Diverticula; Hartmann’s procedure; Peritonitis; Resection and anastomosis
Mesh:
Year: 2019 PMID: 31338117 PMCID: PMC6625026 DOI: 10.1186/s13017-019-0251-4
Source DB: PubMed Journal: World J Emerg Surg ISSN: 1749-7922 Impact factor: 5.469
Modified Hinchey classification
| Modified Hinchey stage | Features |
|---|---|
| Stage 0 | Diverticula with or without wall thickening of the colon |
| Stage 1 | Diverticulitis with a confined pericolic phlegmon or abscess |
| Stage 1a | Phlegmon with inflammatory reaction in pericolic fat tissue |
| Stage 1b | Confined pericolic abscess (< 5 cm) close to the inflammatory site |
| Stage 2 | Diverticulitis with abscess distant from the primary inflammatory site (intra-abdominal, retroperitoneal, or pelvic) |
| Stage 2a | Amenable to percutaneous drainage |
| Stage 2b | Complex abscess associated with a possible fistula |
| Stage 3 | Generalized purulent peritonitis |
| Stage 4 | Fecal peritonitis |
Fig. 1PRISMA flow diagram of the search strategy
Study demographics and outcomes for the HP and PRA group
| Observational studies | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Belmonte | 1996 | 27 | NR | NR | 1 | 3.7% | Open | 85 | 3 | NR | NR | 16 | 2 | 2.4% | Open |
| Berry | 1989 | 6 | NR | NR | 3 | 50.0% | Open | 1 | NR | NR | NR | NR | 0 | 0.0% | Open |
| Binda | 1993 | 17 | NR | 1 | 6 | 35.3% | Open | 9 | NR | 1 | NR | NR | 1 | 11.1% | Open 30, lap 4 |
| Drumm | 1984 | 5 | NR | NR | 1 | 20.0% | Open | 3 | NR | NR | NR | NR | 2 | 66.7% | NR |
| Gawlick | 2012 | 1678 | NR | 226 | 104 | 6.2% | NR | 340 | NR | 40 | NR | 210 | 19 | 5.6% | Open |
| Gooszen | 2001 | 19 | NR | NR | 4 | 21.1% | Open | 21 | NR | NR | NR | 32 | 3 | 14.3% | Open |
| Hold | 1990 | 31 | NR | NR | 6 | 19.4% | Open | 16 | NR | NR | NR | 5 | 3 | 18.8% | Open |
| Makela | 2002 | 47 | NR | NR | 6 | 12.8% | Open | 1 | NR | NR | NR | NR | 0 | 0.0% | Open |
| Medina | 1991 | 3 | NR | NR | 1 | 33.3% | Open | 3 | 0 | 0 | NR | NR | 0 | 0.0% | Open |
| Nagorney | 1985 | 84 | NR | NR | 6 | 7.1% | Open | 4 | NR | NR | NR | 4 | 0 | 0.0% | Open |
| Peoples | 1990 | 25 | NR | NR | 6 | 24.0% | Open | 11 | 0 | NR | NR | NR | 2 | 18.2% | Open |
| Regenet | 2003 | 33 | 5 | 9 | 4 | 12.1% | Open | 27 | 3 | 2 | 3 | 27 | 3 | 11.1% | Open |
| Richter | 2006 | 5 | NR | NR | 3 | 60.0% | Open | 36 | 1 | NR | NR | 3 | 4 | 11.1% | Open |
| Saccomani | 1993 | 7 | NR | NR | 3 | 42.9% | Open | 11 | 0 | NR | NR | 5 | 1 | 9.1% | Open |
| Schilling | 2001 | 42 | 3 | NR | 3 | 7.1% | Open | 13 | NR | NR | NR | NR | 1 | 7.7% | Open |
| Thaler | 2000 | 62 | NR | NR | 22 | 35.5% | Open | 20 | NR | NR | NR | NR | 4 | 20.0% | Open |
| Trenti | 2011 | 60 | NR | 19 | 27 | 45.0% | Open | 27 | 3 | 10 | NR | 5 | 2 | 7.4% | Open |
| Tucci | 1996 | 7 | NR | NR | 1 | 14.3% | Open | 1 | NR | NR | 0 | NR | 0 | 0.0% | Open |
| Tudor | 1994 | 40 | NR | NR | 10 | 25.0% | Open | 8 | 0 | NR | NR | NR | 6 | 75.0% | Open |
| Vennix | 2016 | 240 | NR | NR | 18 | 7.5% | Open | 67 | NR | NR | NR | NR | 0 | 0.0% | Open |
| Vermeulen | 2007 | 95 | NR | NR | 36 | 37.9% | Open | 26 | NR | NR | NR | NR | 7 | 26.9% | Open |
| Wedell | 1997 | 15 | NR | NR | 4 | 26.7% | Open | 14 | 0 | NR | NR | 4 | 1 | 7.1% | Open |
| 2548 | 8 | 255 | 275 | 10.8% | 744 | 7 | 53 | 3 | 295 | 61 | 8.2% | ||||
| Randomized control trials (RCTs) | |||||||||||||||
| Binda | 2012 | 56 | NR | 20 | 6 | 11% | Open 53,lap 3 | 34 | 1 | 15 | NR | 34 | 1 | 2.9% | Open |
| Bridoux | 2017 | 52 | NR | NR | 3 | 6% | Open | 50 | 2 | NR | NR | 50 | 1 | 2.0% | Open |
| Oberkofler | 2012 | 30 | NR | NR | 4 | 13% | Open | 32 | NR | NR | NR | 32 | 3 | 9.4% | Open |
| 138 | 0 | 20 | 13 | 9.4% | 116 | 3 | 15 | 0 | 116 | 5 | 4.3% | ||||
Fig. 2Mortality for the PRA and HP groups as reported in observational studies
Fig. 3Mortality for the PRA and HP groups as reported in RCTs
Fig. 4Wound infection rates for the PRA and HP groups
Wound infection rates between HP and PRA
| Author | Year | Hartmann ( | Hartmann’s wound infection | PRA ( | PRAs wound infection |
|---|---|---|---|---|---|
| Binda | 1993 | 17 | 1 | 9 | 1 |
| Binda | 2012 | 56 | 20 | 34 | 15 |
| Gawlick | 2012 | 1678 | 226 | 340 | 40 |
| Regenet | 2003 | 33 | 9 | 27 | 2 |
| Trenti | 2011 | 60 | 19 | 27 | 10 |
| 1844 | 275 | 437 | 68 | ||
| 14.9% | 15.6% | ||||